82.JPG)
Global Minimal Residual Disease Market Size is valued at USD 1.4 Bn in 2024 and is predicted to reach USD 4.6 Bn by the year 2034 at a 12.8% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
- Precision oncology, which tailors cancer treatment to the molecular characteristics of an individual's cancer, is a key driver of the MRD market.
- Increasing the sensitivity of MRD detection methods contributes to increasing the accuracy of treatment response assessment.
- North America dominated the market and accounted for a revenue share of global revenue in 2024.
The sophisticated nature of MRD detection methods, including next-generation sequencing (NGS), flow cytometry, and polymerase chain reaction (PCR), present challenges Minimal residual disease, also known as measurable residual disease or MRD, refers to the preclinical stages of diseases such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and multiple myeloma (MM). After treatment, the cancer cells that remain in the body are referred to as a minimal residual disease. These cancer cells are undetected by imaging or physical exams, but sophisticated laboratory tests can discover them. The minimal residual disease is an essential indicator of disease progression and therapy response. The growing importance of the test is expected to drive growth in the worldwide minimum residual disease market in the coming years.
The global incidence of cancer has increased dramatically, which is projected to play a vital role in expanding the global minimal residual illness market. Patients are expected to see more precision in treatment using novel technology. These factors are likely to have an impact on growth. Furthermore, favorable government and private-sector initiatives for developing and adopting NGS technologies, technological advancements in cloud computing and data integration, and the availability of a technologically advanced healthcare research framework are all stimulating market growth. Additionally, the improved regulatory and reimbursement landscape for NGS-based diagnostic tests and increased genome mapping initiatives will fuel market expansion throughout the forecast period.
Market Segmentation:
The minimal residual disease market is segmented on the product, technology, application and end user. Based on product, the minimal residual disease market is divided into assay kits & reagents, instruments. Based on the technology, the minimal residual disease market is divided into polymerase chain reaction, next-generation sequencing, flow cytometry, and other technologies. Based on the Application, the minimal residual disease market is segmented into hematological malignancies, lymphoma, solid tumors, multiple myeloma, and other applications. Based on the end user, the minimal residual disease market is segmented into hospitals & specialty clinics, diagnostic laboratories, academic & research institutes, and other end users.
The Assay Kits & Reagents segment is accounted as a major contributor to the minimal residual disease market.
Based on product, the minimal residual disease market is divided into assay kits & reagents, instruments. Among these, The Assay Kits & Reagents segment leads the MRD detection market due to its frequent and recurring use, as each test requires fresh reagents and assay kits. This segment benefits from the growing demand for repeat testing to monitor MRD levels during and after treatment, making it essential for effective disease management. Additionally, the expanding use of MRD detection in personalized medicine and clinical trials further fuels the demand for these consumables. In contrast, instruments such as flow cytometers and PCR machines represent a smaller yet stable market share, primarily driven by infrastructure investment rather than test volume.
The Polymerase Chain Reaction segment witnessed growth at a rapid rate.
Based on the technology, the minimal residual disease market is divided into polymerase chain reaction, next-generation sequencing, flow cytometry, and other technologies. Among these, the Polymerase Chain Reaction (PCR) segment has traditionally dominated the MRD detection market due to its widespread use, high specificity, and cost-effectiveness in routine clinical monitoring. However, Next-Generation Sequencing (NGS) is emerging as the fastest-growing segment, driven by its ultra-high sensitivity and ability to detect a broad spectrum of genetic alterations, making it increasingly favored in clinical trials and personalized treatment approaches. Flow cytometry also holds a significant share, especially in acute leukemias, offering rapid and relatively affordable results, though with lower sensitivity.
The North American Minimal Residual Disease Market Holds A Significant Regional Revenue Share.
The North American minimal residual disease market is expected to register the highest market share in revenue shortly. The rising prevalence of blood malignancies and the increased investment in MRD research by government and private groups have grown healthcare affordability in the United States and the rise in knowledge and awareness among individuals in this region. In addition, Asia Pacific is projected to grow rapidly in the global minimal residual disease market due to government initiatives and large-scale genome sequencing studies funding to develop targeted treatments to contribute to market growth. Furthermore, the existence of key organizations and industries and the quick spread of paternity testing, genealogy, and personal health awareness drive market growth in this area over the forecast period.
Recent Developments:
- In Feb 2022, Personalis, Inc. and the Moores Cancer Center at the University of California San Diego Health partnered to offer clinical diagnostic testing for patients with advanced solid tumours and haematological malignancies. The Moores Cancer Center is recognized as a Comprehensive Cancer Center by the National Cancer Institute. The relationship facilitated the integration of Personalis' advanced and extensive genomic tumour profiling test into the healthcare services provided by UC San Diego. This enabled healthcare professionals and cancer patients to benefit from the test's ability to inform FDA-approved therapy decisions and provide access to potential treatment options in clinical trials.
Competitive Landscape
Some major key players in the Minimal Residual Disease Market:
- Adaptive Biotechnologies,
- ARUP Laboratories,
- Bio-Rad Laboratories Inc.,
- Cergentis B.V.,
- Hoffmann-La Roche Ltd.,
- ICON Plc,
- Invivoscribe Inc.,
- Laboratory Corporation of America Holdings,
- Mission Bio,
- Natera Inc.,
- NeoGenomics Laboratories,
- OPKO Health Inc.,
- Sysmex Corporation
Minimal Residual Disease Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 1.4 Bn |
|
Revenue Forecast In 2034 |
USD 4.6 Bn |
|
Growth Rate CAGR |
CAGR of 12.8% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn,and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Product, Technology, Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ; France; Italy; Spain; South Korea; South East Asia; |
|
Competitive Landscape |
F. Hoffmann-La Roche Ag, Laboratory Corporation of America Holdings, Guardant Health, Inc, Sysmex Corporation, NEOGENOMICS Laboratories, MOLECULARMD, Adaptive Biotechnologies, ARCHERDX, Bio-Rad Laboratories, Inc, Natera, Inc, OPKO Health, Inc, GENETRON Health, Quest Diagnostics, Inc, ASURAGEN, Inc, INVIVOSCRIBE, Inc, Arup Laboratories Inc, Mission Bio, Inc, ERGENTIS B.V |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
